- Home
- RVYL vs NERV Comparison
RVYL vs NERV Comparison
Compare RVYL & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVYL
- NERV
- Stock Information
- Founded
- RVYL 2007
- NERV 2007
- Country
- RVYL United States
- NERV United States
- Employees
- RVYL N/A
- NERV N/A
- Industry
- RVYL Professional Services
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- RVYL Consumer Discretionary
- NERV Health Care
- Exchange
- RVYL Nasdaq
- NERV Nasdaq
- Market Cap
- RVYL 10.3M
- NERV 12.0M
- IPO Year
- RVYL N/A
- NERV 2014
- Fundamental
- Price
- RVYL $0.26
- NERV $1.91
- Analyst Decision
- RVYL Hold
- NERV Hold
- Analyst Count
- RVYL 1
- NERV 1
- Target Price
- RVYL N/A
- NERV $5.00
- AVG Volume (30 Days)
- RVYL 2.2M
- NERV 21.0K
- Earning Date
- RVYL 08-12-2025
- NERV 08-12-2025
- Dividend Yield
- RVYL N/A
- NERV N/A
- EPS Growth
- RVYL N/A
- NERV N/A
- EPS
- RVYL N/A
- NERV 0.83
- Revenue
- RVYL $54,357,000.00
- NERV N/A
- Revenue This Year
- RVYL $27.50
- NERV N/A
- Revenue Next Year
- RVYL $35.71
- NERV N/A
- P/E Ratio
- RVYL N/A
- NERV $2.35
- Revenue Growth
- RVYL N/A
- NERV N/A
- 52 Week Low
- RVYL $0.25
- NERV $1.15
- 52 Week High
- RVYL $2.35
- NERV $3.06
- Technical
- Relative Strength Index (RSI)
- RVYL 30.61
- NERV 51.54
- Support Level
- RVYL $0.25
- NERV $1.87
- Resistance Level
- RVYL $0.33
- NERV $2.32
- Average True Range (ATR)
- RVYL 0.03
- NERV 0.15
- MACD
- RVYL -0.00
- NERV -0.01
- Stochastic Oscillator
- RVYL 10.31
- NERV 28.76
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.